12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Erivedge vismodegib: Interim Phase Ib/II data

Interim data from 70 evaluable patients with recurrent or metastatic pancreatic cancer in a double-blind, U.S. Phase Ib/II trial showed that once-daily 150 mg oral vismodegib plus gemcitabine led to a median PFS of 3.7 months vs. 2.4 months for placebo plus gemcitabine. There were no complete or partial responses and 49 cases of stable disease in patients receiving vismodegib vs. 3 complete responses, 11 partial responses and...

Read the full 318 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >